Treatment of brain tumors is increasingly informed by biomarkers. One use is to
appropriately group tumors with similar genetic/genomic characteristics and to design trials …

The spectrum and diversity of primary brain tumors has made prognostic determinations
based purely on clinicopathologic variables inexact. For the most frequently occurring and …

Brain tumors exhibit heterogeneous profile with anomalous hemodynamics. In spite of
significant advances at diagnostic and therapeutic fronts in the past couple of decades, the …

Gene therapy tailored for use in brain tumours has shown reasonable efficacy in preliminary
clinical trials. Researchers are excited at the prospects of further developing this treatment …

GENE THERAPY RESEARCH HAS been stymied by unanswered questions about whether
the therapeutic genes are integrated into the DNA of the targeted cells and whether the …

Prediction of medulloblastoma clinical outcome is crucial to personalizing treatment, both to
identify high‐risk patients for aggressive or alternative therapy and to spare those at low risk …

Multimodal therapy of glioblastoma (GBM) reveals inter-individual variability in terms of
treatment outcome. Here, we examined whether a miRNA signature can be defined for the a …

High-grade gliomas (HGGs) nearly always recur after standard initial treatment, and the
resulting mixture of recurrent tumor and treatment-induced reactive changes presents major …

Only a subset of patients with newly diagnosed glioblastoma (GBM) exhibit a response to
standard therapy. To date, a biomarker panel with predictive power to distinguish treatment …